CS
MCID: CRZ001
MIFTS: 70

Crouzon Syndrome (CS) malady

Categories: Genetic diseases, Rare diseases, Eye diseases, Bone diseases, Fetal diseases

Aliases & Classifications for Crouzon Syndrome

About this section

Aliases & Descriptions for Crouzon Syndrome:

Name: Crouzon Syndrome 52 35 11 71 48 24 25 70 12 50 13
Crouzon Craniofacial Dysostosis 48 24 25 54 70
Craniofacial Dysostosis 11 25 39
Craniofacial Dysostosis Syndrome 25 27
Craniofacial Dysostosis Type 1 48 68
Craniofacial Dysostosis Type I 24 70
Crouzon's Disease 11 25
 
Crouzons Disease 25 27
Crouzon Disease 48 54
Cfd1 48 70
Craniofacial Dysostosis, Type 1; Cfd1 25
Craniofacial Dysarthrosis 25
Cs 70

Characteristics:

Orphanet epidemiological data:

54
crouzon craniofacial dysostosis:
Inheritance: Autosomal dominant; Prevalence: 1-9/1000000 (Europe); Age of onset: Infancy,Neonatal; Age of death: normal life expectancy

HPO:

64
crouzon syndrome:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 123500
Disease Ontology11 DOID:2339
ICD1030 Q75.1
MeSH39 D003394
SNOMED-CT62 28861008
NCIt45 C84653
Orphanet54 ORPHA207
ICD10 via Orphanet31 Q75.1

Summaries for Crouzon Syndrome

About this section
NIH Rare Diseases:48 Crouzon syndrome is a disorder characterized by early fusion of certain skull bones (craniosynostosis). this prevents normal growth of the skull, which can affect the shape of the head and face. signs and symptoms of crouzon syndrome may include wide-set, bulging eyes; strabismus (misalignment of the eyes); a small, "beak-shaped" nose; and an underdeveloped upper jaw. other features may include dental problems, hearing loss, and/or cleft lip and palate. the severity of signs and symptoms can vary among affected people, even within a family. intelligence is usually normal, but intellectual disability may be present. crouzon syndrome is caused by changes (mutations) in the fgfr2 gene and is inherited in an autosomal dominant manner. treatment may involve surgeries to prevent complications, improve function, and aid in healthy psychosocial development. last updated: 6/8/2016

MalaCards based summary: Crouzon Syndrome, also known as crouzon craniofacial dysostosis, is related to crouzon syndrome with acanthosis nigricans and apert syndrome, and has symptoms including seizures, frequent headaches and Array. An important gene associated with Crouzon Syndrome is FGFR2 (Fibroblast Growth Factor Receptor 2), and among its related pathways are Angiogenesis (WikiPathways) and Syndecan-4-mediated signaling events. Affiliated tissues include bone, eye and skin, and related mouse phenotypes are hearing/vestibular/ear and neoplasm.

Disease Ontology:11 A craniosynostosis that involves premature fusion of certain skull bones. This early fusion prevents the skull from growing normally and affects the shape of the head and face. The disease is associated with mutations in the FGFR2 gene.

Genetics Home Reference:25 Crouzon syndrome is a genetic disorder characterized by the premature fusion of certain skull bones (craniosynostosis). This early fusion prevents the skull from growing normally and affects the shape of the head and face.

OMIM:52 Crouzon syndrome is an autosomal dominant disorder characterized by craniosynostosis causing secondary alterations of... (123500) more...

UniProtKB/Swiss-Prot:70 Crouzon syndrome: An autosomal dominant syndrome characterized by craniosynostosis, hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.

Wikipedia:71 Crouzon syndrome is an autosomal dominant genetic disorder known as a branchial arch syndrome.... more...

Related Diseases for Crouzon Syndrome

About this section

Diseases related to Crouzon Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 126)
idRelated DiseaseScoreTop Affiliating Genes
1crouzon syndrome with acanthosis nigricans33.9FGFR1, FGFR2, FGFR3
2apert syndrome27.7ALX3, BMP6, DCN, ERF, FGF13, FGF2
3craniofacial dysostosis with diaphyseal hyperplasia12.0
4craniofacial dysostosis arthrogryposis progeroid appearence11.9
5cockayne syndrome11.6
6xeroderma pigmentosum, group d11.5
7cowden syndrome 111.4
8gorlin-chaudhry-moss syndrome11.4
9xeroderma pigmentosum, group b11.4
10xeroderma pigmentosum, group g11.4
11xeroderma pigmentosum, group f11.4
12cockayne syndrome, type a11.2
13diabetes mellitus, noninsulin-dependent11.0
14cerebral creatine deficiency syndrome 211.0
15cerebral creatine deficiency syndrome11.0
16bartonellosis11.0
17cat-scratch disease11.0
18critical illness polyneuropathy11.0
19mitochondrial cardiomyopathy11.0
20cpt deficiency, hepatic, type ii10.9
21x-linked sideroblastic anemia with ataxia10.9
22carnitine palmitoyltransferase ii deficiency10.9
23cowden disease10.9
24craniofacial dyssynostosis10.9
25potocki-shaffer syndrome10.9
26c syndrome10.7
27xeroderma pigmentosum-cockayne syndrome complex10.7
28pkp1-related ectodermal dysplasia/skin fragility syndrome10.2FGFR1, FGFR2
29pitx3-related anterior segment mesenchymal dysgenesis10.2FGFR1, FGFR2
30antley-bixler syndrome without genital anomalies or disordered steroidogenesis10.2FGFR2, FGFR3
31cervical spinal canal and spinal cord meningioma10.2FGFR2, FGFR3
32acanthosis nigricans10.2
33bladder diffuse clear cell adenocarcinoma10.2FGF2, TGFB1
34acrofacial dysostosis, palagonia type10.2FGFR1, FGFR2
35familial porphyria cutanea tarda10.2FGFR1, FGFR2, FGFR3
36hartsfield syndrome10.1FGFR1, FGFR2, FGFR3
37pointer syndrome10.1FGFR1, FGFR2, FGFR3
38osteoglophonic dysplasia10.1FGFR1, FGFR2, FGFR3
39joubert syndrome-310.1FGF13, FGF2
40anal paget's disease10.1FGF2, TGFB1
41thanatophoric dysplasia, type i10.1FGFR1, FGFR2, FGFR3
42saddan10.1FGFR1, FGFR2, FGFR3
43t cell immunodeficiency primary10.1FGF2, FGFR1, FGFR3
44anhidrosis10.1BMP6, TGFB1
45ovarian epithelial cancer10.1FGF2, FGFR1, FGFR3
46hypogonadotropic hypogonadism 2 with or without anosmia10.1FGFR1, FGFR2, FGFR3
47immature teratoma of ovary10.1FGF13, FGF2
48discharging ear10.1BMP6, TGFB1
49muenke syndrome10.1FGF13, FGFR2, FGFR3
50speech and communication disorders10.1BMP6, TGFB1

Graphical network of the top 20 diseases related to Crouzon Syndrome:



Diseases related to crouzon syndrome

Symptoms & Phenotypes for Crouzon Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

123500

Clinical features from OMIM:

123500

Human phenotypes related to Crouzon Syndrome:

 54 64 (show all 47)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 narrow palate64 54 Occasional (29-5%) HP:0000189
2 hydrocephalus64 54 Occasional (29-5%) HP:0000238
3 brachycephaly64 54 Frequent (79-30%) HP:0000248
4 turricephaly64 54 Frequent (79-30%) HP:0000262
5 hypertelorism64 54 Frequent (79-30%) HP:0000316
6 hypoplasia of the maxilla64 54 Frequent (79-30%) HP:0000327
7 high forehead64 54 Very frequent (99-80%) HP:0000348
8 hearing impairment54 Occasional (29-5%)
9 conductive hearing impairment64 54 Frequent (79-30%) HP:0000405
10 convex nasal ridge64 54 Occasional (29-5%) HP:0000444
11 choanal atresia64 54 Occasional (29-5%) HP:0000453
12 strabismus64 54 Frequent (79-30%) HP:0000486
13 ptosis64 54 Frequent (79-30%) HP:0000508
14 conjunctivitis64 54 Frequent (79-30%) HP:0000509
15 proptosis64 54 Frequent (79-30%) HP:0000520
16 iris coloboma64 54 Occasional (29-5%) HP:0000612
17 amblyopia64 54 Occasional (29-5%) HP:0000646
18 optic atrophy64 54 Occasional (29-5%) HP:0000648
19 abnormality of the skull54 Very frequent (99-80%)
20 acanthosis nigricans64 54 Occasional (29-5%) HP:0000956
21 melanocytic nevus64 54 Occasional (29-5%) HP:0000995
22 hypopigmented skin patches64 54 Occasional (29-5%) HP:0001053
23 cerebellar hypoplasia64 54 Frequent (79-30%) HP:0001321
24 abnormal facial shape64 54 Very frequent (99-80%) HP:0001999
25 frontal bossing64 54 Very frequent (99-80%) HP:0002007
26 respiratory insufficiency64 54 Occasional (29-5%) HP:0002093
27 arnold-chiari malformation64 54 Frequent (79-30%) HP:0002308
28 headache64 54 Occasional (29-5%) HP:0002315
29 increased intracranial pressure64 54 Frequent (79-30%) HP:0002516
30 abnormality of the sacrum64 54 Occasional (29-5%) HP:0005107
31 multiple suture craniosynostosis64 54 Very frequent (99-80%) HP:0011324
32 narrow internal auditory canal64 54 Occasional (29-5%) HP:0011386
33 midface retrusion64 54 Frequent (79-30%) HP:0011800
34 mandibular prognathia64 HP:0000303
35 atresia of the external auditory canal64 HP:0000413
36 visual impairment64 HP:0000505
37 shallow orbits64 HP:0000586
38 dental crowding64 HP:0000678
39 intellectual disability64 HP:0001249
40 seizures64 HP:0001250
41 abnormality of the nasopharynx64 HP:0001739
42 abnormality of the cervical spine64 HP:0003319
43 craniofacial dysostosis64 HP:0004439
44 coronal craniosynostosis64 HP:0004440
45 sagittal craniosynostosis64 HP:0004442
46 lambdoidal craniosynostosis64 HP:0004443
47 sleep apnea64 HP:0010535

UMLS symptoms related to Crouzon Syndrome:


seizures, frequent headaches

MGI Mouse Phenotypes related to Crouzon Syndrome according to GeneCards Suite gene sharing:

41 (show all 18)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.1FGF2, FGFR1, FGFR2, FGFR3, MSX2
2MP:00020069.0DCN, FGF2, FGFR2, FGFR3, TGFB1
3MP:00053718.5ALX3, FGFR1, FGFR2, FGFR3, MSX2
4MP:00028738.5DCN, ERF, FGFR1, FGFR2, FGFR3, MSX2
5MP:00053698.2DCN, FGF2, FGFR1, FGFR2, MSX2, TGFB1
6MP:00053808.1ALX3, ERF, FGFR1, FGFR2, MSX2, TGFB1
7MP:00107718.0DCN, FGFR1, FGFR2, FGFR3, MSX2, TGFB1
8MP:00053827.5ALX3, DCN, ERF, FGFR1, FGFR2, FGFR3
9MP:00053817.3ALX3, DCN, FGFR1, FGFR2, FGFR3, MSX2
10MP:00053917.2ALX3, DCN, FGF2, FGFR1, FGFR2, FGFR3
11MP:00053977.2DCN, ERF, FGF2, FGFR1, FGFR2, FGFR3
12MP:00053897.1ALX3, BMP6, DCN, FGF2, FGFR1, FGFR2
13MP:00053846.7ALX3, DCN, ERF, FGF13, FGF2, FGFR1
14MP:00053866.7ALX3, DCN, FGF13, FGF2, FGFR1, FGFR2
15MP:00036316.6ALX3, ERF, FGF13, FGF2, FGFR1, FGFR2
16MP:00053786.5ALX3, BMP6, DCN, ERF, FGFR1, FGFR2
17MP:00107686.3ALX3, DCN, ERF, FGF13, FGF2, FGFR1
18MP:00053906.2ALX3, BMP6, DCN, ERF, FGF2, FGFR1

Drugs & Therapeutics for Crouzon Syndrome

About this section

Drugs for Crouzon Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Tranexamic AcidapprovedPhase 4, Phase 32771197-18-85526
Synonyms:
08455_FLUKA
1197-17-7
1197-18-8
1ceb
3-14-00-00868 (Beilstein Handbook Reference)
4-(Aminomethyl)-Cyclohexanecarboxylic Acid
4-(Aminomethyl)cyclohexanecarboxylic acid
4-(aminomethyl)cyclohexane-1-carboxylic acid
857653_ALDRICH
A0236
AB00052260
AB1003647
AC-4687
AC1L1KJH
AC1Q50F3
AC1Q546D
AC1Q5U04
ALBB-006013
AMCA
AMCHA
AMH
AR-1F6595
Acide tranexamique
Acide tranexamique [INN-French]
Acido tranexamico
Acido tranexamico [INN-Spanish]
Acidum tranexamicum
Acidum tranexamicum [INN-Latin]
Amikapron
Amstat
Anvitoff
BAY 3517
BPBio1_000069
BRN 2207452
BSPBio_000061
BSPBio_002837
CAS-1197-18-8
CHEBI:48669
CHEMBL292500
CHEMBL877
CID5526
CL 65336
CL-65336
Carxamin
Cyclocapron
Cyklokapron
Cyklokapron (TN)
D01136
DB00302
DV 79
DV-79
DV79
DivK1c_000655
EINECS 214-818-2
Emorhalt
Exacyl
Frenolyse
HMS1568D03
HMS1921F08
HMS2092P03
HMS502A17
Hexapromin
Hexatron
I04-0993
IDI1_000655
KABI 2161
KBio1_000655
KBio2_001871
KBio2_004439
KBio2_007007
KBio3_002337
KBioGR_000511
 
KBioSS_001871
LS-56611
LS-56612
LT00159441
Mastop
MolPort-001-792-390
MolPort-002-512-008
NCGC00016569-01
NCGC00016569-02
NCGC00016569-03
NCGC00094944-01
NCGC00094944-02
NINDS_000655
NSC 291305
NSC291305
Oprea1_786414
Prestwick0_000171
Prestwick1_000171
Prestwick2_000171
Prestwick3_000171
Prestwick_476
RP 18,429
Rikavarin
Rikavarin (TN)
Rikavarin-S
SPBio_000689
SPBio_001982
SPECTRUM1502026
STK503668
STOCK1N-16183
Spectrum2_000655
Spectrum3_001189
Spectrum4_000046
Spectrum5_001258
Spectrum_001391
Spiramin
Tamcha
Tranex
Tranexamate
Tranexamic acid (JP15/USAN/INN)
Tranexamic acid [USAN:INN:BAN:JAN]
Tranexamic acid cis-form
Tranexamsaeure
Tranexan
Tranexmic acid
Tranhexamic acid
Trans AMCHA
Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid
Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid
Trans-p-(Aminomethyl)cyclohexanecarboxylic
Transamin
Transamin (TN)
Transamlon
Trasamlon
UNII-6T84R30KC1
Ugurol
WLN: L6TJ AVQ D1Z -T
cis-4-(Aminomethyl)cyclohexanecarboxylic acid
cis-4-Aminomethylcyclohexane-1-carboxylic acid
cis-AMCHA
t-AMCHA
tranexamic acid
tranexmic acid
trans-1-Aminomethylcyclohexane-4-carboxylic acid
trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid
trans-4-(Aminomethyl)cyclohexane-carboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester
trans-4-Aminomethylcyclohexane-1-carboxylic acid
trans-4-aminomethylcyclohexane-1-carboxylic acid
trans-Amcha
trans-Tranexamic acid
trans-p-(Aminomethyl)cyclohexanecarboxylic acid
2Antifibrinolytic AgentsPhase 4, Phase 3, Phase 2, Phase 1484
3HemostaticsPhase 4, Phase 3, Phase 2, Phase 11443
4CoagulantsPhase 4, Phase 3, Phase 2, Phase 11500
5MitogensPhase 4, Phase 2, Phase 11617
6
SimvastatinapprovedPhase 251979902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
7
Valproic Acidapproved, investigationalPhase 232799-66-13121
Synonyms:
(N-C3H7)2CHCOOH
(S)-2-propyl-4-pentanoate
(S)-2-propyl-4-pentanoic acid
2 PP (base)
2-N-Propyl-N-valeric acid
2-Propyl-Pentanoate
2-Propyl-Pentanoic acid
2-Propylpentanoate
2-Propylpentanoic Acid
2-Propylpentanoic acid
2-Propylvaleric Acid
2-Propylvaleric acid
2-n-Propyl-n-valeric acid
2-n-propyl-n-valeric acid
2-propyl-pentanoic acid
2-propylvaleric acid
4-Heptanecarboxylic acid
4-heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
AC1L1F7T
AC1Q2ULA
AI3-10500
APO-divalproex
Abbott 44090
Acide valproique
Acide valproique [INN-French]
Acide valproique [inn-french]
Acido valproico
Acido valproico [INN-Spanish]
Acido valproico [inn-spanish]
Acidum valproicum
Acidum valproicum [INN-Latin]
Acidum valproicum [inn-latin]
Alti-Valproic
Alti-valproic
Apo-valproic
Apo-valproic syrup
Avugane
BIDD:GT0858
BRN 1750447
Baceca
C07185
CHEBI:39867
CHEMBL109
CID3121
CPD000499581
Convulex
Convulsofin
D00399
DB00313
DOM-divalproex
DOM-valproic
DOM-valproic acid E.C.
DPA
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetic acid
Di-N-propylessigsaure
Di-N-propylessigsaure [german]
Di-n-propylacetic acid
Di-n-propylessigsaeure
Di-n-propylessigsaure
Di-n-propylessigsaure [German]
Di-n-propylessigsäure
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
DivK1c_000273
Divalproex
Dom-Valproic
Dom-valproate
Dom-valproic acid
Dom-valproic acid syrup
EINECS 202-777-3
Epiject I.V.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
KBio2_004845
 
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
MLS001076682
MLS001335927
MLS001335928
MLS002415770
Med Valproic
Med valproic
MolPort-001-791-895
Mylproin
Myproate
Myproic Acid
Myproic acid
N-DPA
N-Dipropylacetic acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
NINDS_000273
NSC 93819
NSC93819
Novo-Valproic
Novo-Valproic - ECC
Novo-divalproex
Novo-valproic
Novo-valproic soft gel cap
Nu-Valproic
Nu-valproic
P0823
P6273_SIGMA
PEAC
PHL-valproate
PHL-valproic acid
PHL-valproic acid E.C.
PMS-Divalproex
PMS-Valproic Acid
PMS-valproate
PMS-valproic acid
PMS-valproic acid E.C.
Penta-Valproic
Penta-valproic
Propylvaleric acid
Ratio-Valproic - ECC
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
SBB065764
SMR000499581
SPBio_000912
Sandoz valproic
Savicol
Semisodium Valproate
Sodium hydrogen divalproate
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Spectrum_000521
Sprinkle
Stavzor
UNII-614OI1Z5WI
VALPROIC ACID
VPA
Valcote
Valparin
Valproate
Valproate semisodique [French]
Valproate semisodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
Valproic Acid, Sodium Salt (2:1)
Valproic acid
Valproic acid (USP)
Valproic acid USP
Valproic acid USP24
Valproic acid [USAN:INN:BAN]
Valproic acid [usan:ban:inn]
Valproinsaeure
Valproinsäure
Vupral
WLN: QVY3 & 3
acide valproïque
acidum valproicum
di-n-propylacetic acid
n-DPA
n-Dipropylacetic acid
nchembio.79-comp4
nchembio815-comp21
valproate
valproic acid
ácido valproico
8
Aminocaproic Acidapproved, investigationalPhase 2, Phase 12660-32-2564
Synonyms:
.epsilon. S
.epsilon.-Aminocaproic acid
.epsilon.-Aminohexanoic acid
.epsilon.-Leucine
.epsilon.-Norleucine
.omega.-Aminocaproic acid
.omega.-Aminohexanoic acid
1319-82-0
177 J.D
177 J.D.
1cea
3kiv
6 Aminocaproic Acid
6 Aminohexanoic Acid
6-Amino-Hexanoate
6-Amino-Hexanoic acid
6-Amino-N-hexanoate
6-Amino-N-hexanoic acid
6-Amino-n-hexanoic acid
6-Aminocaproate
6-Aminocaproic acid
6-Aminohexanoate
6-Aminohexanoic acid
6-amino-hexanoic acid
6-amino-n-caproate
6-amino-n-caproic acid
6-aminohexanoate
6-aminohexanoic acid
60-32-2
87867-96-7
93208-38-9
A 7824
A0312
A2504_SIGMA
A7824_SIGMA
AB00051911
AC-035
AC1L19IP
AC1Q54EY
ACS
AI3-14512
AKOS000118734
AMICAR
AMINOCAPROIC
Acepramin
Acepramine
Acid, 6-Aminocaproic
Acid, 6-Aminohexanoic
Acid, epsilon-Aminocaproic
Acide aminocaproique
Acide aminocaproique [French]
Acide aminocaproique [INN-French]
Acide aminocaproque
Acide aminocaproïque
Acido aminocaproico
Acido aminocaproico [DCIT,Spanish]
Acido aminocaproico [INN-Spanish]
Acidum Aminocaproicum
Acidum aminocaproicum
Acidum aminocaproicum [INN-Latin]
Acidum aminocaproicum [Latin]
Acikaprin
Afibrin
Ahx
Amicar
Amicar (TN)
Amicar, |A-amino caproic acid, |A-Ahx, 6-aminohexanoic acid, Aminocaproic acid
Amikar
Aminocaproate
Aminocaproic
Aminocaproic Acid In Plastic Container
Aminocaproic Acids
Aminocaproic acid
Aminocaproic acid (USP)
Aminocaproic acid (USP/INN)
Aminocaproic acid [USAN:BAN:INN]
Aminocaproic acid [USAN:INN:BAN]
Aminocapronsäure
Aminohexanoic acid
Aminokapron
Atsemin
BIDD:GT0162
BPBio1_001056
BRN 0906872
BSPBio_000960
C02378
C3BDD377-8F43-4BEC-900A-D5850050BA82
C6H13NO2
CAS-60-32-2
CBDivE_004370
CCRIS 7706
CHEBI:16586
CHEMBL1046
CID564
CL 10304
CL-10304
CY 116
CY-116
CY116
Caplamin
Capracid
Capralense
Capramol
Capranol
Caproamin
Caprocid
Caprolisin
D00160
D015119
DB00513
DB04134
DivK1c_000551
EACA
EACS
EINECS 200-469-3
EPSILON-AMINOCAPROIC ACID
EU-0100082
Eaca
Eaca kabi
Epsamon
 
Epsicaprom
Epsicapron
Epsikapron
Epsilcapramin
Epsilcapramine
Epsillon-Aminocaproate
Epsillon-Aminocaproic acid
Epsillon-Aminocaproic acid' Epsilcapramin
Epsilon S
Epsilon-Aminocaproic Acid
Epsilon-Aminocapronsaeure
Epsilon-aminocapronzuur
H-6-Ahx-OH
H-EAhx-OH
H-epsilon-Acp-OH
HEXANOIC ACID,6-AMINO
HMS1570P22
HMS1920C07
HMS2091I07
HMS501L13
HSDB 3005
Hemocaprol
Hemopar
Hepin
IDI1_000551
InChI=1/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9
Ipsilon
JD 177
KBio1_000551
KBio2_000398
KBio2_002966
KBio2_005534
KBioGR_000586
KBioSS_000398
Kyselina omega-aminokapronova
Kyselina omega-aminokapronova [Czech]
LMFA01100035
LS-7191
Lopac-A-7824
Lopac0_000082
MLS001335991
MLS002695931
MolPort-001-779-881
NCGC00015092-01
NCGC00015092-02
NCGC00015092-03
NCGC00015092-07
NCGC00093587-01
NCGC00093587-02
NCGC00093587-03
NCGC00093587-04
NINDS_000551
NSC 26154
NSC 400230
NSC-26154
NSC212532
NSC26154
NSC400230
Omega-Aminocaproate
Omega-Aminocaproic acid
Omega-Aminohexanoate
Omega-Aminohexanoic acid
Prestwick0_000960
Prestwick1_000960
Prestwick2_000960
Prestwick3_000960
Respramin
S04-0132
S1671_Selleck
SMR000059162
SPBio_000202
SPBio_003109
SPECTRUM1500114
STK246894
Spectrum2_000131
Spectrum4_000143
Spectrum5_000780
Spectrum_000038
TL8003819
UNII-U6F3787206
WLN: Z5VQ
Z
acide aminocaproque
amicar
bmse000394
e-Amino-N-hexanoate
e-Amino-N-hexanoic acid
e-Aminocaproate
e-Aminocaproic acid
e-Aminocaproic acid USP
e-Aminohexanoate
e-Aminohexanoic acid
e-Leucine
e-Norleucine
epsilcapramine
epsilon Aminocaproic Acid
epsilon S
epsilon-Ahx
epsilon-Amino-N-hexanoate
epsilon-Amino-N-hexanoic acid
epsilon-Amino-n-caproic acid
epsilon-Amino-n-hexanoic acid
epsilon-Aminocaproate
epsilon-Aminocaproic acid
epsilon-Aminocaproic acid (JAN)
epsilon-Aminocaproic acid USP
epsilon-Aminohexanoate
epsilon-Aminohexanoic acid
epsilon-Leucine
epsilon-Norleucine
epsilon-S
epsilon-aminocaproate
nchembio.104-comp21
nchembio.2007.30-comp14
omega-Aminocaproic acid
omega-Aminohexanoic acid
w-Aminocaproate
w-Aminocaproic acid
w-Aminohexanoate
w-Aminohexanoic acid
Ácido aminocapróico
9
BenzocaineapprovedPhase 1, Phase 220161994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
10
ponatinibapprovedPhase 232943319-70-824826799
Synonyms:
AP 24534
AP24534
 
Iclusig
Ponatinibum
ponatinib
11tannic acidapproved, NutraceuticalPhase 1, Phase 22016
12Lipid Regulating AgentsPhase 22766
13Anticholesteremic AgentsPhase 22025
14Neurotransmitter AgentsPhase 218340
15Hypolipidemic AgentsPhase 22785
16AntimetabolitesPhase 212054
17Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 21998
18Psychotropic DrugsPhase 26430
19Tranquilizing AgentsPhase 24265
20Histone Deacetylase InhibitorsPhase 2569
21Antimanic AgentsPhase 2814
22AnticonvulsantsPhase 22695
23Central Nervous System DepressantsPhase 213403
24GABA AgentsPhase 21684
25Protein Kinase InhibitorsPhase 23689
26PONATINIB Phase 2
27Liver ExtractsPhase 1, Phase 24067
28PhytosterolNutraceuticalPhase 1, Phase 2118
29tyrosineNutraceuticalPhase 1, Phase 2699
30ImmunoglobulinsPhase 16394
31AntibodiesPhase 16394
32
Adenosineapproved, investigational41958-61-760961
Synonyms:
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-D-Ribofuranose
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-delta-Ribofuranose
1odi
2fqy
2gl0
30143-02-3
4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside
46946-45-6
46969-16-8
58-61-7
6-Amino-9-.beta.-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9beta-delta-ribofuranosyl-9H-purine
9-(beta-D-Arabinofuranosyl)adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyladenine
9beta-D-Ribofuranosyladenine
9beta-D-ribofuranosyl-9H-Purin-6-amine
9beta-delta-Ribofuranosyladenine
9beta-delta-ribofuranosyl-9H-Purin-6-amine
A0152
A4036_SIGMA
A9251_SIGMA
AC1L1U8O
AC1Q1ID3
AC1Q52XU
ADN
AI3-52413
Ade-Rib
Ade-rib
Adenin riboside
Adenine 9-beta-D-arabinofuranoside
Adenine deoxyribonucleoside
Adenine nucleoside
Adenine riboside
Adenine-9-beta-D-ribofuranoside
Adenine-9beta-D-Ribofuranoside
Adenine-9beta-delta-Ribofuranoside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosina
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine, homopolymer
Adenosinum
Adensoine
Adenyldeoxyriboside
Ado
Adénosine
BB_NC-0565
BSPBio_001796
Bio1_000437
 
Bio1_000926
Bio1_001415
Boniton
C00212
CCRIS 2557
CHEBI:16335
CHEMBL477
CID60961
Caswell No. 010B
D000241
D00045
DB00640
Deoxyadenosine
Desoxyadenosine
EA6C60C2-6AFB-4264-A2F0-541373DB950E
EINECS 200-389-9
FT-0082881
HMS1920A13
HMS2091G13
KBio3_001296
LS-15085
MEDR-640
MLS000069638
MLS002153227
MolPort-001-838-229
Myocol
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NSC 627048
NSC 7652
NSC627048
NSC7652
Nucleocardyl
Pallacor
Polyadenosine
Polyriboadenosine
S1647_Selleck
SDCCGMLS-0003108.P003
SMR000058216
SPBio_001194
SPECTRUM1500107
SR 96225
SR-96225
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum3_000288
TL8003749
UNII-K72T3FS567
USAF CB-10
V0098
Vidarabine
ZINC02169830
adenine-D-ribose
adenosine
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-D-Ribofuranoside, adenine-9
beta-delta-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.2007.56-comp13
nchembio.64-comp4
nchembio706-5
33
Mentholapproved26062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
34Peripheral Nervous System Agents23689
35Vasodilator Agents3543
36Analgesics11733
37Anti-Arrhythmia Agents3093
38
Bilirubin116635-65-45280352
Synonyms:
(4Z,15Z)-Bilirubin IXa
(Z,Z)-Bilirubin IXa
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionic acid
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-Biline-8,12-dipropanoate
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-Biline-8,12-dipropanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
 
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
Bilirubin
Bilirubin IX-alpha
Cholerythrin
Hematoidin
39Protective Agents7443
40Antioxidants3050
41Anesthetics9596
42Calcium, Dietary5713
43CalamusNutraceutical459

Interventional clinical trials:

(show top 50)    (show all 55)
idNameStatusNCT IDPhase
1The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis SurgeryRecruitingNCT02188576Phase 4
2Tranexamic Acid for Craniofacial SurgeryTerminatedNCT00722436Phase 4
3Comparison of a Bone Product to Bone Dust in Ossification of Small Calvarial Defects.WithdrawnNCT01006148Phase 4
4Blood Loss and Transfusion Requirement in Infants Treated With Tranexamic AcidUnknown statusNCT01094977Phase 3
5Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz SyndromeUnknown statusNCT00004347Phase 2
6Clinical Trial of Fat Grafts Supplemented With Adipose-derived Regenerative CellsCompletedNCT01674439Phase 2
7Treatment of the Cholesterol Defect in Smith-Lemli-Opitz SyndromeCompletedNCT00272844Phase 1, Phase 2
8Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz SyndromeCompletedNCT00114634Phase 2
9Prenatal Screening For Smith-Lemli-Opitz SyndromeCompletedNCT00070850Phase 2
10Simvastatin Therapy in Smith-Lemli-Opitz SyndromeCompletedNCT00064792Phase 2
11Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic TrialCompletedNCT01619644Phase 2
12A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome PatientsCompletedNCT00961896Phase 2
13Efficacy of Amicar for Children Having Craniofacial SurgeryRecruitingNCT02229968Phase 2
14A Phase II, Single Arm Study of BGJ398 in Patients With Advanced CholangiocarcinomaRecruitingNCT02150967Phase 2
15Dovitinib for Gastric Cancer With FGFR2 AmplificationRecruitingNCT01719549Phase 2
16Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 FusionsRecruitingNCT02265341Phase 2
17Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic AlterationsActive, not recruitingNCT01752920Phase 1, Phase 2
18Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck CancerNot yet recruitingNCT02706691Phase 2
19Amicar Pharmacokinetics of Children Having Craniofacial SurgeryCompletedNCT00912119Phase 1
20Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)TerminatedNCT02368951Phase 1
21Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related ConditionsUnknown statusNCT01306994
22SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol SupplementationUnknown statusNCT01434745
23Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz SyndromeUnknown statusNCT01356420
24The Effect of Gender on the Consumption of Pain Medication in Infants Undergoing Craniosynostosis Repair or Untethering of Cord in ITUUnknown statusNCT01996163
25Clinical and Molecular Characterisation of Orofaciodigital Syndromes and Other Clinical Phenotypes Secondary to Mutations in the OFD1 GeneUnknown statusNCT01962129
26Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African AmericansCompletedNCT00017732
27Child and Infant Learning ProjectCompletedNCT00077831
28Genetic Analysis of Craniosynostosis, Philadelphia TypeCompletedNCT00367796
29Qualitative and Quantitative Study Which Aims to Determine the Specifics of the Announcement for the Diagnosis of Patients With Craniosynostosis and Their Parents to Better Support Them in Their CareCompletedNCT02287805
30Effect of Tranexamic Acid Based on Pharmacokinetics in Pediatric Patients Undergoing Craniosynostosis Surgery: Randomized Controlled TrialCompletedNCT02180321
31Nautilus: Dynamic Craniotomy; New Surgical Technique and Preliminary ResultsCompletedNCT01672619
32Treatment of Cranial Molding Deformities in Preterm InfantsCompletedNCT02366936
33National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular ConditionsCompletedNCT01322165
34Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon SyndromeRecruitingNCT01144741
35Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)RecruitingNCT02224677
36Natural History of Craniofacial Anomalies and Developmental Growth VariantsRecruitingNCT02639312
37Genetic and Functional Analysis of Craniometaphyseal Dysplasia (CMD)RecruitingNCT01630460
38Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)RecruitingNCT01773278
39Study of Smith-Lemli-Opitz SyndromeRecruitingNCT00001721
40MRI for Non-invasive Evaluation of Brain StressRecruitingNCT01898650
41Network Of Clinical Research Studies On Craniosynostosis, Skull Malformations With Premature Fusion Of Skull BonesRecruitingNCT03025763
42Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT01793168
43Optic Nerve Sheath Diameter in CraniosynostosisRecruitingNCT03131245
44Osteogenic Profiling of Tissue From Children With CraniosynostosisRecruitingNCT00773643
45Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)RecruitingNCT00106977
46Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis RepairRecruitingNCT02483702
47UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational ResourceRecruitingNCT01401998
48Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced OsteomalaciaRecruitingNCT01660308
49Clinical and Molecular Investigations Into CiliopathiesActive, not recruitingNCT00068224
50Role of Mesenchymal Stem Cells in Fat GraftingNot yet recruitingNCT02494752

Search NIH Clinical Center for Crouzon Syndrome


Cochrane evidence based reviews: craniofacial dysostosis

Genetic Tests for Crouzon Syndrome

About this section

Genetic tests related to Crouzon Syndrome:

id Genetic test Affiliating Genes
1 Crouzon Syndrome27 24 FGFR2
2 Craniofacial Dysostosis27

Anatomical Context for Crouzon Syndrome

About this section

MalaCards organs/tissues related to Crouzon Syndrome:

36
Bone, Eye, Skin, Trachea, Brain, Testes

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Crouzon Syndrome:
id TissueAnatomical CompartmentCell Relevance
1 BoneRostral Skull Membranous BonesIntramembrenous Osteocytes Affected by disease

Publications for Crouzon Syndrome

About this section

Articles related to Crouzon Syndrome:

(show top 50)    (show all 176)
idTitleAuthorsYear
1
Crouzon syndrome with multiple supernumerary teeth. (28091449)
2017
2
The effect of early fusion of the spheno-occipital synchondrosis on midface hypoplasia and obstructive sleep apnea in patients with Crouzon syndrome. (28479031)
2017
3
Anesthetic Implications in a Child with Crouzon Syndrome. (28298794)
2017
4
Midface Distraction Osteogenesis Using a Modified External Device With Elastic Distraction for Crouzon Syndrome. (28060091)
2017
5
FGFR2 mutation in a Chinese family with unusual Crouzon syndrome. (27803855)
2016
6
Raised intracranial pressure in Crouzon syndrome: incidence, causes, and management. (26613275)
2016
7
High Le Fort I osteotomy for correction of mid-face deformity in Crouzon syndrome. (27092811)
2016
8
Molecular analysis of FGFR 2 and associated clinical observations in two Chinese families with Crouzon syndrome. (27430617)
2016
9
Crouzon syndrome: Virtual planning of surgical treatment by application of internal distractors. (27563623)
2016
10
Individualized therapy for treating obstructive sleep apnea in pediatric Crouzon syndrome patients. (27424047)
2016
11
The Phenotypes of Spheno-Occipital Synchondrosis in Patients With Crouzon Syndrome. (27391494)
2016
12
Crouzon Syndrome: Report in a Family. (26894196)
2016
13
Surgical Treatment of V-pattern Exotropia in Crouzon Syndrome. (26098546)
2015
14
Bilateral congenital cholesteatoma of the temporal bone in Crouzon syndrome. (25993748)
2015
15
Family of Crouzon Syndrome Represents the Evolution of the Frontofacial Monobloc Advancement Technique: From Immediate Movement to Monobloc Distraction to Monobloc Bipartition Distraction. (26267562)
2015
16
Bilateral meningoencephaloceles with cerebrospinal fluid rhinorrhea after facial advancement in the Crouzon syndrome. (26302737)
2015
17
Crouzon Syndrome: Relationship of Eye Movements to Pattern Strabismus. (26176876)
2015
18
Lumboatrial shunt in a patient with Crouzon syndrome complicated by pseudotumor cerebri. (26021731)
2015
19
Monobloc Le Fort III Distraction Osteogenesis for Correction of Severe Fronto-orbital and Midface Hypoplasia in Pediatric Crouzon Syndrome. (25650655)
2015
20
A Novel Technique Using Customized Headgear for Fixation of Rigid External Distraction Device in an Infant With Crouzon Syndrome. (26594993)
2015
21
Deep Venous Thrombosis in Teen With Crouzon Syndrome Post-Le Fort III Osteotomy With Rigid External Distraction. (26595005)
2015
22
Crouzon Syndrome: Visual Diagnosis. (26283152)
2015
23
S267P Mutation in FGFR2: First Report in a Patient With Crouzon Syndrome. (25759927)
2015
24
Crouzon syndrome: Ophthalmologic complications in an untreated adult patient. (26194556)
2015
25
The C342R Mutation in FGFR2 Causes Crouzon Syndrome With Elbow Deformity. (25759925)
2015
26
Revisiting Crouzon syndrome: reviewing the background and management of a multifaceted disease. (25245177)
2014
27
Correction of infraorbital and malar deficiency using costal osteochondral graft along with orthognathic surgery in Crouzon syndrome. (25153066)
2014
28
A novel FGFR2 mutation in tyrosine kinase II domain, L617F, in Crouzon syndrome. (23913723)
2014
29
Orbitofrontal monobloc advancement for Crouzon syndrome. (24530078)
2014
30
Non surgical treatment of Crouzon syndrome. (25209230)
2014
31
Bilateral squamosal suture synostosis: A rare form of isolated craniosynostosis in Crouzon syndrome. (25071892)
2014
32
Apparently synonymous substitutions in FGFR2 affect splicing and result in mild Crouzon syndrome. (25174698)
2014
33
Identification of causative mutation in a korean family with crouzon syndrome using whole exome sequencing. (25361936)
2014
34
Crouzon syndrome with bony upper airway obstruction: case report and review literature. (24828762)
2014
35
Analysis of FGFR2 gene mutations in two Chinese families with Crouzon syndrome]. (24928000)
2014
36
A case of Crouzon syndrome treated by simultaneous bimaxillary distraction. (23886558)
2014
37
Chiari Type I malformation yielded to the diagnosis of Crouzon syndrome. (24741262)
2014
38
Crouzono-dermo-skeletal syndrome, Crouzon syndrome with acanthosis nigricans syndrome. (24476664)
2014
39
Three-dimensional precise orientation of bilateral auricular trial prosthesis using a facebow for a young adult with Crouzon syndrome. (25096652)
2014
40
The spheno-occipital synchondrosis fuses prematurely in patients with Crouzon syndrome and midface hypoplasia compared with age- and gender-matched controls. (24480760)
2014
41
Crouzon syndrome: relationship of rectus muscle pulley location to pattern strabismus. (24346169)
2014
42
Foramen magnum size and involvement of its intraoccipital synchondroses in Crouzon syndrome. (24281646)
2013
43
Management of Crouzon syndrome in an adult patient. (24378546)
2013
44
Crouzon syndrome and Bent bone dysplasia associated with mutations at the same Tyr-381 residue in FGFR2 gene. (23808569)
2013
45
Psychosocial conditions in adults with Crouzon syndrome: a follow-up study of 31 Swedish patients. (24328900)
2013
46
High le fort I and bilateral split sagittal osteotomy in crouzon syndrome. (23714981)
2013
47
Cutaneous features of Crouzon syndrome with acanthosis nigricans. (23571469)
2013
48
Crouzon syndrome. (22605842)
2012
49
Crouzon syndrome--A case report. (22623473)
2012
50
Crouzon syndrome associated with acanthosis nigricans: prenatal 2D and 3D ultrasound findings and postnatal 3D CT findings. (23986840)
2012

Variations for Crouzon Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Crouzon Syndrome:

70 (show all 37)
id Symbol AA change Variation ID SNP ID
1FGFR2p.Tyr105CysVAR_004112
2FGFR2p.Ser252LeuVAR_004113rs79184941
3FGFR2p.Ser267ProVAR_004118rs121918505
4FGFR2p.Phe276ValVAR_004120
5FGFR2p.Cys278PheVAR_004121rs776587763
6FGFR2p.Gln289ProVAR_004123rs121918497
7FGFR2p.Trp290ArgVAR_004125rs121918501
8FGFR2p.Lys292GluVAR_004126rs121918500
9FGFR2p.Tyr301CysVAR_004127
10FGFR2p.Tyr328CysVAR_004130rs121918493
11FGFR2p.Asn331IleVAR_004131
12FGFR2p.Gly338GluVAR_004133
13FGFR2p.Tyr340HisVAR_004134rs121918489
14FGFR2p.Thr341ProVAR_004135rs121918495
15FGFR2p.Cys342PheVAR_004136
16FGFR2p.Cys342ArgVAR_004137rs121918488
17FGFR2p.Cys342SerVAR_004138rs121918488
18FGFR2p.Cys342TyrVAR_004139rs121918487
19FGFR2p.Ala344GlyVAR_004140rs121918492
20FGFR2p.Ala344ProVAR_004141
21FGFR2p.Ser347CysVAR_004142rs121918494
22FGFR2p.Ser351CysVAR_004143rs121918502
23FGFR2p.Ser354CysVAR_004144rs121918490
24FGFR2p.Val359PheVAR_004146
25FGFR2p.Gly384ArgVAR_004147
26FGFR2p.Gly338ArgVAR_015011
27FGFR2p.Pro263LeuVAR_017261rs779326224
28FGFR2p.Cys278TyrVAR_017263
29FGFR2p.Tyr281CysVAR_017264
30FGFR2p.Ile288SerVAR_017265
31FGFR2p.Trp290GlyVAR_017266rs121918501
32FGFR2p.Ala337ProVAR_017268rs387906676
33FGFR2p.Cys342TrpVAR_017271rs121918496
34FGFR2p.Ser354TyrVAR_017272
35FGFR2p.Ala362SerVAR_017273
36FGFR2p.Asn549HisVAR_017276
37FGFR2p.Arg678GlyVAR_017281

Clinvar genetic disease variations for Crouzon Syndrome:

5 (show all 26)
id Gene Variation Type Significance SNP ID Assembly Location
1FGFR2NM_ 000141.4(FGFR2): c.1025G> A (p.Cys342Tyr)SNVPathogenic/ Likely pathogenicrs121918487GRCh37Chr 10, 123276892: 123276892
2FGFR2NM_ 000141.4(FGFR2): c.1018T> C (p.Tyr340His)SNVPathogenicrs121918489GRCh37Chr 10, 123276899: 123276899
3FGFR2NM_ 000141.4(FGFR2): c.1061C> G (p.Ser354Cys)SNVPathogenicrs121918490GRCh37Chr 10, 123276856: 123276856
4FGFR2NM_ 000141.4(FGFR2): c.1024T> C (p.Cys342Arg)SNVPathogenicrs121918488GRCh37Chr 10, 123276893: 123276893
5FGFR2NM_ 000141.4(FGFR2): c.1024T> A (p.Cys342Ser)SNVPathogenicrs121918488GRCh37Chr 10, 123276893: 123276893
6FGFR2NM_ 000141.4(FGFR2): c.1032G> A (p.Ala344=)SNVPathogenicrs121918491GRCh37Chr 10, 123276885: 123276885
7FGFR2NM_ 000141.4(FGFR2): c.1031C> G (p.Ala344Gly)SNVPathogenicrs121918492GRCh37Chr 10, 123276886: 123276886
8FGFR2NM_ 000141.4(FGFR2): c.983A> G (p.Tyr328Cys)SNVPathogenicrs121918493GRCh37Chr 10, 123276934: 123276934
9FGFR2NM_ 000141.4(FGFR2): c.1040C> G (p.Ser347Cys)SNVPathogenicrs121918494GRCh37Chr 10, 123276877: 123276877
10FGFR2NM_ 000141.4(FGFR2): c.1026C> G (p.Cys342Trp)SNVPathogenicrs121918496GRCh37Chr 10, 123276891: 123276891
11FGFR2NM_ 000141.4(FGFR2): c.866A> C (p.Gln289Pro)SNVPathogenicrs121918497GRCh37Chr 10, 123279566: 123279566
12FGFR2NM_ 000141.4(FGFR2): c.874A> G (p.Lys292Glu)SNVPathogenicrs121918500GRCh37Chr 10, 123279558: 123279558
13FGFR2NM_ 000141.4(FGFR2): c.868T> C (p.Trp290Arg)SNVPathogenicrs121918501GRCh37Chr 10, 123279564: 123279564
14FGFR2NM_ 000141.4(FGFR2): c.868T> G (p.Trp290Gly)SNVPathogenicrs121918501GRCh37Chr 10, 123279564: 123279564
15FGFR2NM_ 000141.4(FGFR2): c.799T> C (p.Ser267Pro)SNVPathogenicrs121918505GRCh37Chr 10, 123279633: 123279633
16FGFR2NM_ 000141.4(FGFR2): c.1576A> G (p.Lys526Glu)SNVPathogenicrs121918507GRCh37Chr 10, 123258105: 123258105
17FGFR2NM_ 000141.4(FGFR2): c.1084+3A> GSNVPathogenicrs879253721GRCh38Chr 10, 121517316: 121517316
18FGFR2NM_ 000141.4(FGFR2): c.1009G> C (p.Ala337Pro)SNVPathogenicrs387906676GRCh37Chr 10, 123276908: 123276908
19FGFR2NM_ 000141.4(FGFR2): c.826T> G (p.Phe276Val)SNVPathogenicrs1057519036GRCh37Chr 10, 123279606: 123279606
20FGFR2NM_ 000141.4(FGFR2): c.842A> G (p.Tyr281Cys)SNVLikely pathogenicrs1057519038GRCh37Chr 10, 123279590: 123279590
21FGFR2NM_ 000141.4(FGFR2): c.869G> C (p.Trp290Ser)SNVPathogenicrs1057519039GRCh38Chr 10, 121520049: 121520049
22FGFR2NM_ 000141.4(FGFR2): c.923A> G (p.Tyr308Cys)SNVPathogenicrs1057519040GRCh37Chr 10, 123279509: 123279509
23FGFR2NM_ 000141.4(FGFR2): c.1007A> G (p.Asp336Gly)SNVPathogenicrs1057519042GRCh38Chr 10, 121517396: 121517396
24FGFR2NM_ 000141.4(FGFR2): c.1012G> C (p.Gly338Arg)SNVPathogenicrs1057519043GRCh38Chr 10, 121517391: 121517391
25FGFR2NM_ 000141.4(FGFR2): c.1013G> A (p.Gly338Glu)SNVPathogenicrs1057519044GRCh38Chr 10, 121517390: 121517390
26FGFR2NM_ 000141.4(FGFR2): c.1645A> C (p.Asn549His)SNVLikely pathogenicrs1057519045GRCh37Chr 10, 123258036: 123258036

Expression for genes affiliated with Crouzon Syndrome

About this section
Search GEO for disease gene expression data for Crouzon Syndrome.

Pathways for genes affiliated with Crouzon Syndrome

About this section

Pathways related to Crouzon Syndrome according to GeneCards Suite gene sharing:

(show all 47)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.8FGF2, FGFR2
29.8FGF2, FGFR1
3
Show member pathways
9.5FGFR1, FGFR2, FGFR3
49.5FGFR1, FGFR2, FGFR3
59.5FGFR1, FGFR2, FGFR3
69.4FGF2, FGFR1, FGFR3
7
Show member pathways
9.3FGF2, FGFR2, TGFB1
89.2FGF2, FGFR1, TGFB1
99.2FGF2, FGFR1, TGFB1
10
Show member pathways
9.2FGF2, FGFR1, FGFR2, FGFR3
11
Show member pathways
9.2FGF2, FGFR1, FGFR2, FGFR3
129.2FGF2, FGFR1, FGFR2, FGFR3
13
Show member pathways
9.2FGF2, FGFR1, FGFR2, FGFR3
14
Show member pathways
9.2FGF2, FGFR1, FGFR2, FGFR3
159.2FGF2, FGFR1, FGFR2, FGFR3
16
Show member pathways
9.2FGF2, FGFR1, FGFR2, FGFR3
17
Show member pathways
9.2FGF2, FGFR1, FGFR2, FGFR3
18
Show member pathways
9.2FGF2, FGFR1, FGFR2, FGFR3
199.1FGF13, FGF2, TGFB1
20
Show member pathways
9.0FGFR1, FGFR2, FGFR3, TGFB1
21
Show member pathways
8.9BMP6, DCN, TGFB1
228.8DCN, FGF2, FGFR1, TGFB1
238.7FGF2, FGFR1, FGFR2, FGFR3, MSX2
24
Show member pathways
8.6FGF2, FGFR1, FGFR2, FGFR3, TGFB1
25
Show member pathways
8.6FGF13, FGF2, FGFR1, FGFR2, FGFR3
268.6FGF13, FGF2, FGFR1, FGFR2, FGFR3
27
Show member pathways
8.6FGF13, FGF2, FGFR1, FGFR2, FGFR3
28
Show member pathways
8.6FGF13, FGF2, FGFR1, FGFR2, FGFR3
29
Show member pathways
8.6FGF13, FGF2, FGFR1, FGFR2, FGFR3
30
Show member pathways
8.6FGF13, FGF2, FGFR1, FGFR2, FGFR3
318.3BMP6, FGF2, FGFR1, FGFR3, TGFB1
328.1BMP6, DCN, FGF2, MSX2, TGFB1
33
Show member pathways
8.1FGF13, FGF2, FGFR1, FGFR2, FGFR3, TGFB1
348.1FGF13, FGF2, FGFR1, FGFR2, FGFR3, TGFB1
35
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
36
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
37
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
38
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
397.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
40
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
41
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
42
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
43
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
44
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
45
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
46
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3
47
Show member pathways
7.5BMP6, FGF13, FGF2, FGFR1, FGFR2, FGFR3

GO Terms for genes affiliated with Crouzon Syndrome

About this section

Cellular components related to Crouzon Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00055767.0BMP6, DCN, FGF13, FGF2, FGFR1, FGFR2

Biological processes related to Crouzon Syndrome according to GeneCards Suite gene sharing:

(show top 50)    (show all 55)
idNameGO IDScoreTop Affiliating Genes
1bone mineralizationGO:003028210.7FGFR2, FGFR3
2branching involved in salivary gland morphogenesisGO:006044510.6FGFR1, FGFR2
3fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex developmentGO:003560710.6FGFR1, FGFR2
4lung-associated mesenchyme developmentGO:006048410.6FGFR1, FGFR2
5mesenchymal cell differentiationGO:004876210.6FGFR1, FGFR2
6midbrain developmentGO:003090110.6FGFR1, FGFR2
7orbitofrontal cortex developmentGO:002176910.6FGFR1, FGFR2
8odontogenesisGO:004247610.6FGFR2, MSX2
9outflow tract septum morphogenesisGO:000314810.6FGFR2, MSX2
10positive regulation of mesenchymal cell proliferationGO:000205310.6FGFR1, FGFR2
11positive regulation of endothelial cell chemotaxis to fibroblast growth factorGO:200054610.5FGF2, FGFR1
12positive regulation of phospholipase C activityGO:001086310.5FGF2, FGFR1
13digestive tract developmentGO:004856510.5FGFR2, TGFB1
14hyaluronan catabolic processGO:003021410.4FGF2, TGFB1
15negative regulation of blood vessel endothelial cell migrationGO:004353710.4FGF2, TGFB1
16positive regulation of blood vessel endothelial cell migrationGO:004353610.4FGF2, TGFB1
17ventricular zone neuroblast divisionGO:002184710.3FGFR1, FGFR2
18frontal suture morphogenesisGO:006036410.3MSX2, TGFB1
19endochondral ossificationGO:000195810.3BMP6, FGFR3
20bone morphogenesisGO:006034910.3FGFR2, FGFR3, MSX2
21endochondral bone growthGO:000341610.3FGFR2, FGFR3, MSX2
22positive regulation of cardiac muscle cell proliferationGO:006004510.2FGF2, FGFR1, FGFR2
23positive regulation of MAPK cascadeGO:004341010.2FGFR1, FGFR2, FGFR3
24positive regulation of phospholipase activityGO:001051810.2FGFR1, FGFR2, FGFR3
25salivary gland morphogenesisGO:000743510.2FGFR1, TGFB1
26ventricular cardiac muscle tissue morphogenesisGO:005501010.2FGFR2, TGFB1
27animal organ morphogenesisGO:000988710.2DCN, FGF2, FGFR2
28protein autophosphorylationGO:004677710.2FGFR1, FGFR2, FGFR3
29embryonic cranial skeleton morphogenesisGO:004870110.2ALX3, FGFR2
30positive regulation of bone mineralizationGO:003050110.1BMP6, TGFB1
31positive regulation of cell divisionGO:005178110.1FGF2, FGFR2, TGFB1
32positive regulation of SMAD protein import into nucleusGO:006039110.1BMP6, TGFB1
33chondrocyte differentiationGO:000206210.1FGFR1, FGFR3, TGFB1
34embryonic forelimb morphogenesisGO:003511510.0ALX3, MSX2
35embryonic hindlimb morphogenesisGO:003511610.0ALX3, MSX2
36positive regulation of phosphatidylinositol 3-kinase activityGO:004355210.0FGF2, FGFR3, TGFB1
37positive regulation of MAP kinase activityGO:004340610.0FGF2, FGFR1, TGFB1
38fibroblast growth factor receptor signaling pathwayGO:00085439.9FGF2, FGFR1, FGFR2, FGFR3
39peptidyl-tyrosine phosphorylationGO:00181089.9FGF2, FGFR1, FGFR2, FGFR3
40phosphatidylinositol phosphorylationGO:00468549.9FGF2, FGFR1, FGFR2, FGFR3
41phosphatidylinositol-3-phosphate biosynthetic processGO:00360929.9FGF2, FGFR1, FGFR2, FGFR3
42phosphatidylinositol-mediated signalingGO:00480159.9FGF2, FGFR1, FGFR2, FGFR3
43positive regulation of GTPase activityGO:00435479.9FGF2, FGFR1, FGFR2, FGFR3
44ureteric bud developmentGO:00016579.8FGFR1, FGFR2, TGFB1
45positive regulation of epithelial cell proliferationGO:00506799.8BMP6, FGFR2, TGFB1
46regulation of phosphatidylinositol 3-kinase signalingGO:00140669.8FGF2, FGFR1, FGFR2, FGFR3
47positive regulation of ERK1 and ERK2 cascadeGO:00703749.8FGF2, FGFR2, FGFR3, TGFB1
48skeletal system developmentGO:00015019.7BMP6, FGFR1, FGFR3
49BMP signaling pathwayGO:00305099.7BMP6, MSX2, TGFB1
50positive regulation of cell proliferationGO:00082849.4FGF2, FGFR1, FGFR2, FGFR3, TGFB1

Molecular functions related to Crouzon Syndrome according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1receptor-receptor interactionGO:009072210.2FGF2, FGFR1
2fibroblast growth factor bindingGO:001713410.2FGFR1, FGFR2, FGFR3
3fibroblast growth factor-activated receptor activityGO:000500710.2FGFR1, FGFR2, FGFR3
4heparin bindingGO:000820110.1FGF2, FGFR1, FGFR2
51-phosphatidylinositol-3-kinase activityGO:00163039.8FGF2, FGFR1, FGFR2, FGFR3
6phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:00469349.8FGF2, FGFR1, FGFR2, FGFR3
7protein tyrosine kinase activityGO:00047139.7FGF2, FGFR1, FGFR2, FGFR3
8cytokine activityGO:00051259.7BMP6, FGF2, TGFB1
9Ras guanyl-nucleotide exchange factor activityGO:00050889.6FGF2, FGFR1, FGFR2, FGFR3
10transmembrane receptor protein tyrosine kinase activityGO:00047149.5FGFR1, FGFR2, FGFR3
11growth factor activityGO:00080839.1BMP6, FGF13, FGF2, TGFB1

Sources for Crouzon Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet